You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDapoxetine
Accession NumberDB04884
TypeSmall Molecule
GroupsInvestigational
DescriptionDapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.
Structure
Thumb
Synonyms
Dapoxetina
Dapoxetinum
External Identifiers
  • LY 210448
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIGB2433A4M3
CAS number119356-77-3
WeightAverage: 305.4134
Monoisotopic: 305.177964363
Chemical FormulaC21H23NO
InChI KeyInChIKey=USRHYDPUVLEVMC-FQEVSTJZSA-N
InChI
InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
IUPAC Name
dimethyl[(1S)-3-(naphthalen-1-yloxy)-1-phenylpropyl]amine
SMILES
CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Phenylpropylamine
  • Naphthalene
  • Aralkylamine
  • Alkyl aryl ether
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of premature ejaculation.
PharmacodynamicsDapoxetine is a selective serotonin reuptake inhibitor currently undergoing trials through Alza (under license from GenuPro, a collaboration between Eli Lilly and PPD). Dapoxetine is a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks. By contrast with SSRIs approved for depression, which take 2 weeks or longer to reach steady-state concentration, dapoxetine has a unique pharmacokinetic profile, with a short time to maximum serum concentration (about 1 h) and rapid elimination (initial half-life of 1-2 h).
Mechanism of actionThe drug's mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT's modulating activity on ejaculation.
Related Articles
AbsorptionRapidly absorbed.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeInitial half-life of 1-2 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9933
Blood Brain Barrier+0.9758
Caco-2 permeable+0.817
P-glycoprotein substrateSubstrate0.5085
P-glycoprotein inhibitor IInhibitor0.6464
P-glycoprotein inhibitor IINon-inhibitor0.8833
Renal organic cation transporterInhibitor0.74
CYP450 2C9 substrateNon-substrate0.7484
CYP450 2D6 substrateSubstrate0.7615
CYP450 3A4 substrateSubstrate0.7727
CYP450 1A2 substrateInhibitor0.9354
CYP450 2C9 inhibitorNon-inhibitor0.7353
CYP450 2D6 inhibitorNon-inhibitor0.5597
CYP450 2C19 inhibitorNon-inhibitor0.7689
CYP450 3A4 inhibitorNon-inhibitor0.8382
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6419
Ames testAMES toxic0.6626
CarcinogenicityNon-carcinogens0.8718
BiodegradationNot ready biodegradable0.9866
Rat acute toxicity2.5199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6032
hERG inhibition (predictor II)Inhibitor0.663
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000837 mg/mLALOGPS
logP4.75ALOGPS
logP4.67ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity96.14 m3·mol-1ChemAxon
Polarizability35 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Safarinejad MR: Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology. 2008 May;33(6):1259-65. Epub 2007 Jul 11. [PubMed:17625501 ]
  2. Cirillo-Penn K, Modi NB: Dapoxetine and paroxetine for the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):315. [PubMed:17909314 ]
  3. McMahon C: Dapoxetine in the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):314-5. [PubMed:17909313 ]
  4. Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. [PubMed:17624269 ]
  5. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9;368(9539):929-37. [PubMed:16962882 ]
  6. Hellstrom WJ, Heintz JW: Treatment of premature ejaculation: new drugs and treatment strategies. Curr Urol Rep. 2006 Nov;7(6):473-8. [PubMed:17052444 ]
  7. Modi NB, Dresser M, Desai D, Edgar C, Wesnes K: Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007 Mar;47(3):315-22. [PubMed:17322143 ]
  8. Payne RE, Sadovsky R: Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med. 2007 May;74 Suppl 3:S47-53. [PubMed:17546831 ]
External Links
ATC CodesG04BX14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dapoxetine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Dapoxetine.
AcarboseDapoxetine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dapoxetine.
AcenocoumarolDapoxetine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dapoxetine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dapoxetine.
Acetylsalicylic acidDapoxetine may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Dapoxetine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dapoxetine.
AlbiglutideDapoxetine may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dapoxetine.
AlfentanilAlfentanil may increase the serotonergic activities of Dapoxetine.
AlfuzosinDapoxetine may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Dapoxetine.
AlmotriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Almotriptan.
AlogliptinDapoxetine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Dapoxetine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dapoxetine.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Dapoxetine.
AmiodaroneThe serum concentration of Dapoxetine can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dapoxetine.
AmitriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amitriptyline.
AmlodipineDapoxetine may increase the orthostatic hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dapoxetine.
AmoxapineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dapoxetine.
AmrinoneDapoxetine may increase the orthostatic hypotensive activities of Amrinone.
AprepitantThe serum concentration of Dapoxetine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dapoxetine.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Dapoxetine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dapoxetine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dapoxetine.
AtazanavirThe serum concentration of Dapoxetine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Dapoxetine.
AtomoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dapoxetine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dapoxetine.
AzelnidipineDapoxetine may increase the orthostatic hypotensive activities of Azelnidipine.
Azilsartan medoxomilDapoxetine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.
AzimilideDapoxetine may increase the orthostatic hypotensive activities of Azimilide.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dapoxetine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine.
BarnidipineDapoxetine may increase the orthostatic hypotensive activities of Barnidipine.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Dapoxetine.
BenazeprilDapoxetine may increase the orthostatic hypotensive activities of Benazepril.
BendroflumethiazideDapoxetine may increase the hyponatremic activities of Bendroflumethiazide.
BenidipineDapoxetine may increase the orthostatic hypotensive activities of Benidipine.
BenmoxinBenmoxin may increase the serotonergic activities of Dapoxetine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dapoxetine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dapoxetine.
BepridilDapoxetine may increase the orthostatic hypotensive activities of Bepridil.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Dapoxetine.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Dapoxetine.
BezitramideBezitramide may increase the serotonergic activities of Dapoxetine.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Dapoxetine.
BoceprevirThe serum concentration of Dapoxetine can be increased when it is combined with Boceprevir.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Dapoxetine.
BortezomibThe serum concentration of Dapoxetine can be increased when it is combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dapoxetine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapoxetine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapoxetine.
BromocriptineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dapoxetine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dapoxetine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Dapoxetine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapoxetine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Dapoxetine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Dapoxetine.
BuspironeThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapoxetine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dapoxetine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dapoxetine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dapoxetine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dapoxetine.
ButorphanolButorphanol may increase the serotonergic activities of Dapoxetine.
CabergolineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cabergoline.
CanagliflozinDapoxetine may increase the hypoglycemic activities of Canagliflozin.
CandesartanDapoxetine may increase the orthostatic hypotensive activities of Candesartan.
CandoxatrilDapoxetine may increase the orthostatic hypotensive activities of Candoxatril.
CaptoprilDapoxetine may increase the orthostatic hypotensive activities of Captopril.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Dapoxetine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dapoxetine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dapoxetine.
CarfentanilCarfentanil may increase the serotonergic activities of Dapoxetine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dapoxetine.
CaroxazoneCaroxazone may increase the serotonergic activities of Dapoxetine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Dapoxetine.
CarvedilolDapoxetine may increase the orthostatic hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Dapoxetine.
CeritinibThe serum concentration of Dapoxetine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dapoxetine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dapoxetine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dapoxetine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dapoxetine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dapoxetine.
ChlorothiazideDapoxetine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dapoxetine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dapoxetine.
ChlorpropamideDapoxetine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dapoxetine.
ChlorthalidoneDapoxetine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dapoxetine.
CilazaprilDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.
CilnidipineDapoxetine may increase the orthostatic hypotensive activities of Cilnidipine.
CimetidineThe metabolism of Dapoxetine can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dapoxetine.
CinnarizineDapoxetine may increase the orthostatic hypotensive activities of Cinnarizine.
CitalopramThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Citalopram.
CitalopramCitalopram may increase the serotonergic activities of Dapoxetine.
ClarithromycinThe serum concentration of Dapoxetine can be increased when it is combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dapoxetine.
ClevidipineDapoxetine may increase the orthostatic hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dapoxetine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dapoxetine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dapoxetine.
ClomipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dapoxetine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapoxetine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapoxetine.
ClotrimazoleThe serum concentration of Dapoxetine can be increased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Dapoxetine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dapoxetine.
CobicistatThe serum concentration of Dapoxetine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dapoxetine.
CodeineCodeine may increase the serotonergic activities of Dapoxetine.
ConivaptanThe serum concentration of Dapoxetine can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Dapoxetine can be increased when it is combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dapoxetine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cyclobenzaprine.
CyclosporineThe serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.
CyproheptadineThe therapeutic efficacy of Dapoxetine can be decreased when used in combination with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dapoxetine.
DapagliflozinDapoxetine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dapoxetine.
DarodipineDapoxetine may increase the orthostatic hypotensive activities of Darodipine.
DarunavirThe serum concentration of Dapoxetine can be increased when it is combined with Darunavir.
DelavirdineThe serum concentration of Dapoxetine can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Dapoxetine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapoxetine.
DesipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dapoxetine.
DesmopressinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dapoxetine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapoxetine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dextromethorphan.
DextromoramideDextromoramide may increase the serotonergic activities of Dapoxetine.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Dapoxetine.
DezocineDezocine may increase the serotonergic activities of Dapoxetine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dapoxetine.
DicoumarolDapoxetine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Dapoxetine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Dapoxetine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dihydroergotamine.
DihydroergotamineThe serum concentration of Dapoxetine can be increased when it is combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Dapoxetine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Dapoxetine.
DiltiazemThe serum concentration of Dapoxetine can be increased when it is combined with Diltiazem.
DiltiazemDapoxetine may increase the orthostatic hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dapoxetine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapoxetine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Dapoxetine.
DisopyramideDapoxetine may increase the hypoglycemic activities of Disopyramide.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dapoxetine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Dapoxetine.
DotarizineDapoxetine may increase the orthostatic hypotensive activities of Dotarizine.
DoxazosinDapoxetine may increase the orthostatic hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Doxepin.
DoxycyclineThe serum concentration of Dapoxetine can be increased when it is combined with Doxycycline.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Dapoxetine.
DPDPEDPDPE may increase the serotonergic activities of Dapoxetine.
DronedaroneThe serum concentration of Dapoxetine can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dapoxetine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dapoxetine.
DulaglutideDapoxetine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dapoxetine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Dapoxetine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dapoxetine.
EfonidipineDapoxetine may increase the orthostatic hypotensive activities of Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Eletriptan.
EmpagliflozinDapoxetine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilDapoxetine may increase the orthostatic hypotensive activities of Enalapril.
EnalaprilatDapoxetine may increase the orthostatic hypotensive activities of Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dapoxetine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dapoxetine.
EperisoneDapoxetine may increase the orthostatic hypotensive activities of Eperisone.
EprosartanDapoxetine may increase the orthostatic hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergotamine.
Erythrityl TetranitrateDapoxetine may increase the orthostatic hypotensive activities of Erythrityl Tetranitrate.
ErythromycinThe serum concentration of Dapoxetine can be increased when it is combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram.
EscitalopramEscitalopram may increase the serotonergic activities of Dapoxetine.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Dapoxetine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dapoxetine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dapoxetine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dapoxetine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapoxetine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dapoxetine.
Ethyl biscoumacetateDapoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dapoxetine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dapoxetine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Dapoxetine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dapoxetine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dapoxetine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dapoxetine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapoxetine.
EtoperidoneDapoxetine may increase the serotonergic activities of Etoperidone.
EtorphineEtorphine may increase the serotonergic activities of Dapoxetine.
ExenatideDapoxetine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Dapoxetine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dapoxetine.
FelodipineDapoxetine may increase the orthostatic hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dapoxetine.
FendilineDapoxetine may increase the orthostatic hypotensive activities of Fendiline.
FenfluramineFenfluramine may increase the serotonergic activities of Dapoxetine.
FentanylThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fentanyl.
FentanylFentanyl may increase the serotonergic activities of Dapoxetine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dapoxetine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dapoxetine.
FluconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dapoxetine.
FlunarizineDapoxetine may increase the orthostatic hypotensive activities of Flunarizine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dapoxetine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dapoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.
FluoxetineFluoxetine may increase the serotonergic activities of Dapoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dapoxetine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dapoxetine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dapoxetine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dapoxetine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dapoxetine.
FluvoxamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluvoxamine.
ForasartanDapoxetine may increase the orthostatic hypotensive activities of Forasartan.
FosamprenavirThe serum concentration of Dapoxetine can be increased when it is combined with Fosamprenavir.
FosinoprilDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Dapoxetine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dapoxetine.
FrovatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Dapoxetine.
GabapentinDapoxetine may increase the orthostatic hypotensive activities of Gabapentin.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dapoxetine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Dapoxetine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Dapoxetine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dapoxetine.
GliclazideDapoxetine may increase the hypoglycemic activities of Gliclazide.
GlimepirideDapoxetine may increase the hypoglycemic activities of Glimepiride.
GlipizideDapoxetine may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dapoxetine.
GlyburideDapoxetine may increase the hypoglycemic activities of Glyburide.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapoxetine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dapoxetine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapoxetine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dapoxetine.
HeroinHeroin may increase the serotonergic activities of Dapoxetine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dapoxetine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Dapoxetine.
HydralazineDapoxetine may increase the orthostatic hypotensive activities of Hydralazine.
HydrochlorothiazideDapoxetine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Dapoxetine.
HydroflumethiazideDapoxetine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Dapoxetine.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Dapoxetine.
IdelalisibThe serum concentration of Dapoxetine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dapoxetine.
ImatinibThe serum concentration of Dapoxetine can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Imipramine.
IndalpineDapoxetine may increase the serotonergic activities of Indalpine.
IndapamideDapoxetine may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Dapoxetine.
IndinavirThe serum concentration of Dapoxetine can be increased when it is combined with Indinavir.
IndoraminDapoxetine may increase the orthostatic hypotensive activities of Indoramin.
Insulin AspartDapoxetine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirDapoxetine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineDapoxetine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineDapoxetine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanDapoxetine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproDapoxetine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Dapoxetine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Dapoxetine.
IproniazidIproniazid may increase the serotonergic activities of Dapoxetine.
IrbesartanDapoxetine may increase the orthostatic hypotensive activities of Irbesartan.
IsavuconazoniumThe serum concentration of Dapoxetine can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Isocarboxazid.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Dapoxetine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dapoxetine.
Isosorbide DinitrateDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Mononitrate.
IsradipineThe serum concentration of Dapoxetine can be increased when it is combined with Isradipine.
IsradipineDapoxetine may increase the orthostatic hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Itraconazole.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapoxetine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dapoxetine.
KetobemidoneKetobemidone may increase the serotonergic activities of Dapoxetine.
KetoconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Dapoxetine.
LabetalolDapoxetine may increase the orthostatic hypotensive activities of Labetalol.
LacidipineDapoxetine may increase the orthostatic hypotensive activities of Lacidipine.
LamotrigineDapoxetine may increase the orthostatic hypotensive activities of Lamotrigine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dapoxetine.
LanreotideDapoxetine may increase the hypoglycemic activities of Lanreotide.
LercanidipineDapoxetine may increase the orthostatic hypotensive activities of Lercanidipine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dapoxetine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Dapoxetine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dapoxetine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Dapoxetine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dapoxetine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Dapoxetine.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Dapoxetine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Dapoxetine.
LevorphanolLevorphanol may increase the serotonergic activities of Dapoxetine.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Dapoxetine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapoxetine.
LinezolidThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Linezolid.
LinezolidLinezolid may increase the serotonergic activities of Dapoxetine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Dapoxetine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Dapoxetine.
LiraglutideDapoxetine may increase the hypoglycemic activities of Liraglutide.
LisinoprilDapoxetine may increase the orthostatic hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lithium.
LofentanilLofentanil may increase the serotonergic activities of Dapoxetine.
LopinavirThe serum concentration of Dapoxetine can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dapoxetine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapoxetine.
LorcaserinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lorcaserin.
LosartanDapoxetine may increase the orthostatic hypotensive activities of Losartan.
LovastatinThe serum concentration of Dapoxetine can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dapoxetine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Dapoxetine.
Lu AA21004Dapoxetine may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine.
Magnesium SulfateDapoxetine may increase the orthostatic hypotensive activities of Magnesium Sulfate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Dapoxetine.
ManidipineDapoxetine may increase the orthostatic hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Maprotiline.
MebanazineMebanazine may increase the serotonergic activities of Dapoxetine.
MecaserminDapoxetine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dapoxetine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dapoxetine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dapoxetine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dapoxetine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dapoxetine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dapoxetine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapoxetine.
MetforminDapoxetine may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Methadone.
MethadoneMethadone may increase the serotonergic activities of Dapoxetine.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Dapoxetine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dapoxetine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dapoxetine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapoxetine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dapoxetine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dapoxetine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dapoxetine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapoxetine.
MethyclothiazideDapoxetine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueDapoxetine may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dapoxetine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Dapoxetine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapoxetine.
MetolazoneDapoxetine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dapoxetine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dapoxetine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Dapoxetine.
MibefradilDapoxetine may increase the orthostatic hypotensive activities of Mibefradil.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapoxetine.
MifepristoneThe serum concentration of Dapoxetine can be increased when it is combined with Mifepristone.
MifepristoneDapoxetine may increase the hypoglycemic activities of Mifepristone.
MiglitolDapoxetine may increase the hypoglycemic activities of Miglitol.
MilnacipranThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Milnacipran.
MilnacipranMilnacipran may increase the serotonergic activities of Dapoxetine.
MinaprineMinaprine may increase the serotonergic activities of Dapoxetine.
MinoxidilDapoxetine may increase the orthostatic hypotensive activities of Minoxidil.
MirtazapineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Moclobemide.
MoclobemideMoclobemide may increase the serotonergic activities of Dapoxetine.
MoexiprilDapoxetine may increase the orthostatic hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dapoxetine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Dapoxetine.
MorphineMorphine may increase the serotonergic activities of Dapoxetine.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapoxetine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Dapoxetine.
NalbuphineNalbuphine may increase the serotonergic activities of Dapoxetine.
NaratriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Naratriptan.
NateglinideDapoxetine may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nefazodone.
NefazodoneThe serum concentration of Dapoxetine can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Dapoxetine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Dapoxetine can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Dapoxetine can be increased when it is combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Dapoxetine.
NicardipineDapoxetine may increase the orthostatic hypotensive activities of Nicardipine.
NifedipineDapoxetine may increase the orthostatic hypotensive activities of Nifedipine.
NiguldipineDapoxetine may increase the orthostatic hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Dapoxetine can be increased when it is combined with Nilotinib.
NiludipineDapoxetine may increase the orthostatic hypotensive activities of Niludipine.
NilvadipineDapoxetine may increase the orthostatic hypotensive activities of Nilvadipine.
NimesulideDapoxetine may increase the orthostatic hypotensive activities of Nimesulide.
NimodipineDapoxetine may increase the orthostatic hypotensive activities of Nimodipine.
NisoldipineDapoxetine may increase the orthostatic hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapoxetine.
NitrendipineDapoxetine may increase the orthostatic hypotensive activities of Nitrendipine.
NitroglycerinDapoxetine may increase the orthostatic hypotensive activities of Nitroglycerin.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dapoxetine.
NormethadoneNormethadone may increase the serotonergic activities of Dapoxetine.
NortriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nortriptyline.
OctamoxinOctamoxin may increase the serotonergic activities of Dapoxetine.
OctreotideDapoxetine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dapoxetine.
OlanzapineDapoxetine may increase the serotonergic activities of Olanzapine.
OlaparibThe serum concentration of Dapoxetine can be increased when it is combined with Olaparib.
OlmesartanDapoxetine may increase the orthostatic hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dapoxetine.
OmapatrilatDapoxetine may increase the orthostatic hypotensive activities of Omapatrilat.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dapoxetine.
OpiumOpium may increase the serotonergic activities of Dapoxetine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dapoxetine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dapoxetine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dapoxetine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dapoxetine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Dapoxetine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dapoxetine.
OxycodoneOxycodone may increase the serotonergic activities of Dapoxetine.
OxymorphoneOxymorphone may increase the serotonergic activities of Dapoxetine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dapoxetine.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dapoxetine.
PargylinePargyline may increase the serotonergic activities of Dapoxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.
ParoxetineParoxetine may increase the serotonergic activities of Dapoxetine.
PasireotideDapoxetine may increase the hypoglycemic activities of Pasireotide.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Dapoxetine.
PentamidineDapoxetine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Dapoxetine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dapoxetine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Dapoxetine.
PerhexilineDapoxetine may increase the orthostatic hypotensive activities of Perhexiline.
PerindoprilDapoxetine may increase the orthostatic hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dapoxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dapoxetine.
PethidineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pethidine.
PethidinePethidine may increase the serotonergic activities of Dapoxetine.
PhenelzineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phenelzine.
PhenelzinePhenelzine may increase the serotonergic activities of Dapoxetine.
PhenindioneDapoxetine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Dapoxetine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dapoxetine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dapoxetine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Dapoxetine.
PhenprocoumonDapoxetine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dapoxetine.
PimozideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pimozide.
PinaveriumDapoxetine may increase the orthostatic hypotensive activities of Pinaverium.
PindololThe serum concentration of Pindolol can be increased when it is combined with Dapoxetine.
PioglitazoneDapoxetine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapoxetine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dapoxetine.
PirlindolePirlindole may increase the serotonergic activities of Dapoxetine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Dapoxetine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Dapoxetine.
PolythiazideDapoxetine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapoxetine.
PosaconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Dapoxetine.
PramlintideDapoxetine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dapoxetine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine.
PrazosinDapoxetine may increase the orthostatic hypotensive activities of Prazosin.
PregabalinDapoxetine may increase the orthostatic hypotensive activities of Pregabalin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dapoxetine.
PrenylamineDapoxetine may increase the orthostatic hypotensive activities of Prenylamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dapoxetine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Dapoxetine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dapoxetine.
ProcarbazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapoxetine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dapoxetine.
PromethazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dapoxetine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dapoxetine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dapoxetine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Dapoxetine.
ProtriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dapoxetine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dapoxetine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapoxetine.
QuinaprilDapoxetine may increase the orthostatic hypotensive activities of Quinapril.
QuinethazoneDapoxetine may increase the hyponatremic activities of Quinethazone.
QuinineDapoxetine may increase the hypoglycemic activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dapoxetine.
RamiprilDapoxetine may increase the orthostatic hypotensive activities of Ramipril.
RanolazineThe serum concentration of Dapoxetine can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rasagiline.
RasagilineRasagiline may increase the serotonergic activities of Dapoxetine.
RemifentanilRemifentanil may increase the serotonergic activities of Dapoxetine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dapoxetine.
RepaglinideDapoxetine may increase the hypoglycemic activities of Repaglinide.
RescinnamineDapoxetine may increase the orthostatic hypotensive activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapoxetine.
RisedronateDapoxetine may increase the orthostatic hypotensive activities of Risedronate.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Dapoxetine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dapoxetine.
RitonavirThe serum concentration of Dapoxetine can be increased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rizatriptan.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dapoxetine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapoxetine.
RosiglitazoneDapoxetine may increase the hypoglycemic activities of Rosiglitazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dapoxetine.
SafrazineSafrazine may increase the serotonergic activities of Dapoxetine.
SaprisartanDapoxetine may increase the orthostatic hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Dapoxetine can be increased when it is combined with Saquinavir.
SaralasinDapoxetine may increase the orthostatic hypotensive activities of Saralasin.
SaxagliptinDapoxetine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapoxetine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapoxetine.
SelegilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Selegiline.
SelegilineSelegiline may increase the serotonergic activities of Dapoxetine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dapoxetine.
SertralineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sertraline.
SertralineSertraline may increase the serotonergic activities of Dapoxetine.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapoxetine.
SildenafilThe serum concentration of Dapoxetine can be increased when it is combined with Sildenafil.
SildenafilDapoxetine may increase the orthostatic hypotensive activities of Sildenafil.
SilodosinDapoxetine may increase the orthostatic hypotensive activities of Silodosin.
SitagliptinDapoxetine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Dapoxetine.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Dapoxetine.
SpiraprilDapoxetine may increase the orthostatic hypotensive activities of Spirapril.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Dapoxetine.
SufentanilSufentanil may increase the serotonergic activities of Dapoxetine.
SulfadiazineDapoxetine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleDapoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleThe serum concentration of Dapoxetine can be increased when it is combined with Sulfisoxazole.
SulfisoxazoleDapoxetine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dapoxetine.
SumatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sumatriptan.
SunitinibDapoxetine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Dapoxetine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dapoxetine.
TadalafilDapoxetine may increase the orthostatic hypotensive activities of Tadalafil.
TamsulosinDapoxetine may increase the orthostatic hypotensive activities of Tamsulosin.
TapentadolThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tapentadol.
TapentadolTapentadol may increase the serotonergic activities of Dapoxetine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Dapoxetine.
TasosartanDapoxetine may increase the orthostatic hypotensive activities of Tasosartan.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Dapoxetine can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Dapoxetine can be increased when it is combined with Telithromycin.
TelmisartanDapoxetine may increase the orthostatic hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapoxetine.
TemocaprilDapoxetine may increase the orthostatic hypotensive activities of Temocapril.
TerazosinDapoxetine may increase the orthostatic hypotensive activities of Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapoxetine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dapoxetine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dapoxetine.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapoxetine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dapoxetine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Dapoxetine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dapoxetine.
ThioridazineDapoxetine may increase the arrhythmogenic activities of Thioridazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dapoxetine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapoxetine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Dapoxetine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dapoxetine.
TiclopidineThe serum concentration of Dapoxetine can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dapoxetine.
TimololThe serum concentration of Timolol can be increased when it is combined with Dapoxetine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapoxetine.
TolazamideDapoxetine may increase the hypoglycemic activities of Tolazamide.
TolbutamideDapoxetine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapoxetine.
Tolfenamic AcidDapoxetine may increase the orthostatic hypotensive activities of Tolfenamic Acid.
ToloxatoneToloxatone may increase the serotonergic activities of Dapoxetine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dapoxetine.
TramadolThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tramadol.
TramadolTramadol may increase the serotonergic activities of Dapoxetine.
TrandolaprilDapoxetine may increase the orthostatic hypotensive activities of Trandolapril.
TranilastDapoxetine may increase the orthostatic hypotensive activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dapoxetine.
TranylcypromineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tranylcypromine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Dapoxetine.
TrazodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dapoxetine.
TrichlormethiazideDapoxetine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dapoxetine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dapoxetine.
TrimazosinDapoxetine may increase the orthostatic hypotensive activities of Trimazosin.
TrimipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dapoxetine.
UdenafilDapoxetine may increase the orthostatic hypotensive activities of Udenafil.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dapoxetine.
ValsartanDapoxetine may increase the orthostatic hypotensive activities of Valsartan.
VardenafilDapoxetine may increase the orthostatic hypotensive activities of Vardenafil.
VenlafaxineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Venlafaxine.
VenlafaxineThe serum concentration of Dapoxetine can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.
VerapamilDapoxetine may increase the orthostatic hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Dapoxetine.
VilazodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vilazodone.
VilazodoneVilazodone may increase the serotonergic activities of Dapoxetine.
VoriconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vortioxetine.
WarfarinDapoxetine may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dapoxetine.
XylometazolineDapoxetine may increase the orthostatic hypotensive activities of Xylometazoline.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dapoxetine.
ZiconotideDapoxetine may increase the orthostatic hypotensive activities of Ziconotide.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dapoxetine.
ZimelidineZimelidine may increase the serotonergic activities of Dapoxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapoxetine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dapoxetine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Zolmitriptan.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dapoxetine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dapoxetine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dapoxetine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dapoxetine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dapoxetine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. [PubMed:17624269 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 05:51 / Updated on August 17, 2016 12:24